Institutional members access full text with Ovid®

Share this article on:

Hepatitis C therapy update

Casey, Lisa C.; Lee, William M.

Current Opinion in Gastroenterology: May 2012 - Volume 28 - Issue 3 - p 188–192
doi: 10.1097/MOG.0b013e3283528e1e
LIVER: Edited by Don Rockey

Purpose of review We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field.

Recent findings Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy.

Summary Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.

Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Correspondence to William M. Lee, MD, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, 5959 Harry Hines Boulevard, Suite 420, Dallas, TX 75390–8887, USA. Tel: +1 214 645 6111; fax: +1 214 645 6114; e-mail: William.Lee@utsouthwestern.edu

© 2012 Lippincott Williams & Wilkins, Inc.